Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Osimertinib Combined With Anlotinib in EGFRm+, Treatment-naïve IIIb/IV NSCLC Patients: a Prospective, Single Arm, Phase Ib/IIa Study

NCT04770688 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT04770688
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04770688 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Osimertinib Combined With Anlotinib in EGFRm+, Treatment-naïve IIIb/IV NSCLC Patients: a Prospective, Single Arm, Phase Ib/IIa Study
Lead sponsor
Shanghai Chest Hospital
Phase
Phase 1/2
Overall status
Completed
Start date
November 19, 2020
Completion date
June 20, 2024
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of lung, locally advanced solid tumor, metastatic cancer, non-small cell lung cancer with egfr mutation